A phase 3 study of fixed dose combinations of fianlimab and cemiplimab versus relatlimab and nivolumab in participants with unresectable or metastatic melanoma.

Disease Types: Melanoma

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A phase 3 study of fixed dose combinations of fianlimab and cemiplimab versus relatlimab and nivolumab in participants with unresectable or metastatic melanoma.

For More Information:

https://clinicaltrials.gov/study/NCT06246916?term=R3767-ONC-22122&rank=1#more-information

A Phase 2, open-label, multicenter study to evaluate efficacy and safety of zanidatamab for the treatment of participants with previously treated HER2-expressing solid tumors (DiscovHER PAN-206) (JZP598-206)

Disease Types: Solid Tumors

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT06695845?term=%20JZP598-206&rank=1

A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM):Successor-1 (CA057-001)

Disease Types: Myelomas

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT05519085?term=CA057-001&rank=1

A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)(Excaliber-RRMM)(CC-220-MM-002)

Disease Types: Myelomas

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT04975997?term=Excaliber-RRMM&rank=1

A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM):SUCCESSOR-2 (CA057008)

Disease Types: Myelomas

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT05552976?term=SUCCESSOR-2&rank=1

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)

Disease Types: Myelomas

Available at: Roanoke

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)

For More Information:

https://clinicaltrials.gov/study/NCT05972135?term=Teclistamab%20in%20Multiple%20myeloma&rank=2

A Randomized, Open-label, Multisite, Phase 3 Study of Zilovertamab Vedotin (MK2140) in Combination With R-CHP versus R-CHOP in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) (waveLINE-010)

Disease Types: Lymphoma

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT06717347?term=waveLINE-010&rank=1

A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma

Disease Types: Lymphoma

Available at: Roanoke

For More Information:

https://clinicaltrials.gov/study/NCT06191744?term=Epcoritamab%20%2B%20Rituximab%20and%20Lenalidomide%20(R2)&rank=4

A Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Disease Types: Lung

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT06646276?term=BMS-986489%20&rank=3

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers

Disease Types: Colon, Hepatic

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers

For More Information:

https://clinicaltrials.gov/study/NCT06596694?term=A%20Phase%201%2F2%20Study%20to%20Evaluate%20the%20Safety%20and%20Efficacy%20of%20Patritumab%20Deruxtecan%20in%20Gastrointestinal%20Cancers&rank=1

A Phase 1/2 Substudy of the MK-9999-U02 Master Protocol to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers

Disease Types: Colon

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 1/2 Substudy of the MK-9999-U02 Master Protocol to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers

For More Information:

https://clinicaltrials.gov/study/NCT06428409?term=MK-2870%20in%20Gastrointestinal&rank=2

A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Disease Types: Breast

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More information:

https://clinicaltrials.gov/study/NCT06103864?term=D7630C00001&rank=1

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Patients with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Disease Types: Head and Neck

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT06256588?term=dostarlimab%20in%20head%20and%20neck%20carcinomas&checkSpell=&rank=1

A phase III randomized, open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Disease Types: Head and Neck

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT06525220?term=MCLA-158-CL03&rank=1

A Phase III, Open-Label, Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Cheomotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Disease Types: Breast

Available at: Roanoke, Salem, Wytheville, Alleghany, Blacksburg

For more information:

https://clinicaltrials.gov/study/NCT06112379?term=%20(D926QC00001)&rank=1

A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Disease Types: Head and Neck

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

clinicaltrials.gov- Petosemtamab trial

A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda (Pembrolizumab) in Subjects with Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer (20210033)

Disease Types: Lung

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

clinicaltrials.gov- ABP234 trial

Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Disease Types: Colon, Solid Tumors

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

For More Information:

clinicaltrials.gov- Petosemtamab trial

A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous trastuzumab deruxtecan treatment (JZP598-303)

Disease Types: Breast

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

Clinicaltrials.gov- Zanidatamab

A Phase 2/3, randomized, double-blind, controlled study of Zanzalintinib (XL092) in combination with pembrolizumab vs pembrolizumab in the first-line treatment of subjects with PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma

Disease Types: Head and Neck

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT06082167?term=PHASE%202%2F3,%20RANDOMIZED,%20DOUBLE-BLIND,%20CONTROLLED%20STUDY%20OF%20ZANZALINTINIB%20(XL092)%20IN%20COMBINATION%20WITH%20PEMBROLIZUMAB%20VS%20PEMBROLIZUMAB%20IN%20THE%20FIRST-LINE%20TREATMENT%20OF%20SUBJECTS%20WITH%20PD-L1%20POSITIVE%20RECURRENT%20OR%20METASTATIC%20HEAD%20AND%20NECK%20SQUAMOUS%20CELL%20CARCINOMA&rank=1

An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC) (CAAA617D12302)

Disease Types: Prostate

Available at: Roanoke

For More information:

https://clinicaltrials.gov/study/NCT05939414?term=An%20International,%20Prospective,%20Open-label,%20Multi-center,%20Randomized%20Phase%20III%20Study%20comparing%20lutetium%20(177Lu)%20vipivotide%20tetraxetan%20versus%20Observation%20to%20delay%20castration%20or%20disease%20recurrence%20in%20adult%20male%20patients%20with%20prostate-specific%20membrane%20antigen%20(PSMA)%20positive%20Oligometastatic%20Prostate%20Cancer%20(OMPC)%20(CAAA617D12302)&rank=1

A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Disease Types: Lymphoma

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT04116437?term=A%20Phase%202,%20Multicenter,%20Single-arm%20Study%20of%20Zanubrutinib%20(BGB-3111)%20in%20Patients%20with%20Previously%20Treated%20B-Cell%20Lymphoma%20Intolerant%20of%20Prior%20Treatment%20with%20Ibrutinib%20and%2For%20Acalabrutinib%20(BGB-3111-215)&rank=1

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The “ELEMENT-MDS” Trial

Disease Types: Hematology

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT05949684?term=A%20Phase%203,%20Open-label,%20Randomized%20Study%20to%20Compare%20the%20Efficacy%20and%20Safety%20of%20Luspatercept%20(ACE-536)%20vs%20Epoetin%20Alfa%20for%20the%20Treatment%20of%20Anemia%20Due%20to%20Revised%20International%20Prognostic%20Scoring%20System%20(IPSS-R)%20Very%20Low,%20Low,%20or%20Intermediate-Risk%20Myelodysplastic%20Syndrome%20(MDS)%20in%20Erythropoiesis-Stimulating%20Agent%20(ESA)-naive%20Participants%20who%20are%20Non-Transfusion%20Dependent%20(NTD):%20The%20%E2%80%9CELEMENT-MDS%E2%80%9D%20Trial&rank=1

A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Disease Types: Lung

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

For More Information:

https://clinicaltrials.gov/study/NCT06246110?term=A%20Phase%202%20Study%20of%20EIK1001%20in%20Combination%20with%20Pembrolizumab%20and%20Chemotherapy%20in%20Patients%20with%20Stage%204%20Non-Small%20Cell%20Lung%20Cancer%20(EIK1001-005)&rank=1

Phase 2 Single Arm Trial with a Safety Lead-in of Tucatinib in Combination with Doxil for the Treatment of HER2+ Metastatic Breast Cancer (BRE 381)

Disease Types: Breast

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

Phase 2 Single Arm Trial with a Safety Lead-in of Tucatinib in Combination with Doxil for the Treatment of HER2+ Metastatic Breast Cancer (BRE 381)

For More Information:

https://clinicaltrials.gov/search?term=Phase%202%20Single%20Arm%20Trial%20with%20a%20Safety%20Lead-in%20of%20Tucatinib%20in%20Combination%20with%20Doxil%20for%20the%20Treatment%20of%20HER2%2B%20Metastatic%20Breast%20Cancer%20(BRE%20381)

A Phase Ib/II, open-label, multicenter study evaluating the safety, activity, and pharmacokinetics of GDC-6036 in combination with other anti-cancer therapies in patients with previously untreated advanced or metastatic non-small cell lung cancer with a KRAS G12C mutation

Disease Types: Lung

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT04449874?term=NSCLC%20G12C%20mutation%20GDC-6036%20&rank=1

A Phase 2 Study of Alisertib in Patients with Extensive Small Cell Lung Cancer

Disease Types: Lung

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 2 Study of Alisertib in Patients with Extensive Small Cell Lung Cancer

For More information:

https://clinicaltrials.gov/study/NCT06095505?term=A%20Phase%202%20Study%20of%20Alisertib%20in%20Patients%20with%20Extensive%20Small%20Cell%20Lung%20Cancer&rank=1

A randomized, phase 3, open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer

Disease Types: Lung

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A randomized, phase 3, open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer

For More Information:

https://clinicaltrials.gov/study/NCT06012435?term=A%20randomized,%20phase%203,%20open-label%20study%20to%20evaluate%20SGN-B6A%20compared%20with%20docetaxel%20in%20adult%20subjects%20with%20previously%20treated%20non-small%20cell%20lung%20cancer%20&rank=1

A Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy

Disease Types: Breast

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT06018337?term=A%20Phase%203,%20Randomized,%20Multi-center,%20Open-label%20Study%20of%20DB-1303%20Versus%20Investigator%27s%20Choice%20Chemotherapy%20in%20Human%20Epidermal%20Growth%20Factor%20Receptor%202%20(HER2)-low,%20Hormone%20Receptor%20Positive%20(HR%2B)%20Metastatic%20Breast%20Cancer%20Patients%20whose%20Disease%20has%20Progressed%20on%20Endocrine%20Therapy&rank=1

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

Disease Types: Breast

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT05633654?term=%20A%20Randomized,%20Open-label,%20Phase%203%20Study%20of%20Adjuvant%20Sacituzumab%20Govitecan%20and%20Pembrolizumab%20Versus%20Treatment%20of%20Physicians%20Choice%20in%20Patients%20with%20Triple%20Negative%20Breast%20Cancer%20Who%20Have%20Residual%20Invasive%20Disease%20After%20Surgery%20and%20Neoadjuvant%20Therapy&rank=1

A Phase 3, Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) and Have Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) for Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Disease Types: Prostate

Available at: Alleghany, Blacksburg, Roanoke, Wytheville, Salem

For More Information:

https://clinicaltrials.gov/study/NCT06136650?term=MK-5684&rank=4

A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy

Disease Types: Prostate

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT06136624?term=A%20Phase%203%20Randomized,%20Open-label%20Study%20of%20MK-5684%20Versus%20Alternative%20Abiraterone%20Acetate%20or%20Enzalutamide%20in%20Participants%20With%20Metastatic%20Castration-resistant%20Prostate%20Cancer%20(mCRPC)%20Previously%20Treated%20With%20Next-generation%20Hormonal%20Agent%20(NHA)%20and%20Taxane-based%20Chemotherapy&rank=1

A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Disease Types: Lung

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT05607550?term=NCT05607550&rank=1

A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Disease Types: Lung

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

For More Information:

https://clinicaltrials.gov/study/NCT05074810?term=NCT05074810&rank=1

A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Disease Types: Breast

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT05774951?term=NCT05774951&rank=1

A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

Disease Types: Colon

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT04793958?term=A%20Randomized%20Phase%203%20Study%20of%20MRTX849%20in%20Combination%20with%20Cetuximab%20Versus%20Chemotherapy%20in%20Patients%20with%20Advanced%20Colorectal%20Cancer%20with%20KRAS%20G12C%20Mutation%20with%20Disease%20Progression%20On%20or%20After%20Standard%20First-Line%20Therapy&rank=1

A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence

Disease Types: Breast

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More information:

https://clinicaltrials.gov/ct2/show/NCT05514054?term=Adjuvant+Imlunestrant+vs+Standard+Adjuvant+Endocrine+Therapy+in+breast+cancer&draw=2&rank=1

A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy

Disease Types: Breast

Available at: Alleghany, Blacksburg, Roanoke, Wytheville, Salem

For More Information:

https://clinicaltrials.gov/ct2/show/NCT05501886?term=Gedatolisib+in+Combination+with+Palbociclib+and+Fulvestrant&draw=2&rank=4

A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, with locally advanced, unresectable, Stage III Non-Small Cell Lung Cancer

Disease Types: Lung

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/ct2/show/NCT05170204?term=A+Phase+I-III%2C+Multicenter+Study+Evaluating+the+Efficacy+and+Safety+of+Multiple+Therapies+in+Cohorts+of+Patients+Selected+According+to+Biomarker+Status%2C+with+locally+advanced%2C+unresectable%2C+Stage+III+Non-Small+Cell+Lung+Cancer&draw=2&rank=1

A Phase 1B/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker adaptive study of Tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory Follicular Lymphoma (EZH-302)

Disease Types: Lymphoma

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/ct2/show/NCT04224493?term=A+Phase+1B%2F3+Double-Blind%2C+Randomized%2C+Active-Controlled%2C+3-Stage%2C+Biomarker+adaptive+study+of+Tazemetostat+or+placebo+in+combination+with+lenalidomide+plus+rituximab+in+subjects+with+relapsed%2Frefractory+Follicular+Lymphoma+%28EZH-302%29&draw=2&rank=1

Master Screening Study to determine biomarker status and potential trial eligibility for patients with malignant tumors

Disease Types: Lung

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

Master Screening Study to determine biomarker status and potential trial eligibility for patients with malignant tumors

For More Information:

https://clinicaltrials.gov/ct2/show/NCT05419375?term=Master+Screening+Study+to+determine+biomarker+status+and+potential+trial+eligibility+for+patients+with+malignant+tumors&draw=2&rank=1

A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment

Disease Types: Melanoma

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment

For more information:

https://clinicaltrials.gov/ct2/show/NCT04609566?cond=A+phase+2+study+of+brentuximab+vedotin+in+combination+with+pembrolizumab+in+subjects+with+metastatic+solid+malignancies+after+progression+on+prior+PD-1+inhibitor+treatment&draw=2&rank=1